| (Values in U.S. Thousands) | Jun, 2022 | Mar, 2022 | Dec, 2021 | Sep, 2021 | Jun, 2021 |
| Sales | 221,000 | 207,000 | 223,000 | 187,000 | 201,000 |
| Sales Growth | +6.76% | -7.17% | +19.25% | -6.97% | +11.67% |
| Net Income | 48,000 | 41,000 | 35,000 | 27,000 | 63,000 |
| Net Income Growth | +17.07% | +17.14% | +29.63% | -57.14% | -21.25% |
Indivior Plc ADR (INVVY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Indivior PLC was incorporated in England and Wales on September 26, 2014 as a public limited company. It is a pharmaceutical company. It is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence.